JTCS Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Yoshimasa Miyauchi
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okuma, T.
Right arrow Articles by Miyauchi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okuma, T.
Right arrow Articles by Miyauchi, Y.

J Thorac Cardiovasc Surg 1994;108:823-829
© 1994 Mosby, Inc.

GENERAL THORACIC SURGERY

Preoperative chemotherapy for esophageal cancer based on chemosensitivity testing

Toshitada Okuma, MD, Masakazu Yoshioka, MD, Susumu Isechi, MD, Keiichiro Kondo, MD, Yoichi Tabira, MD, Yoshitsugu Torigoe, MD, Yoshimasa Miyauchi, MD


Kumamoto, Japan

From the First Department of Surgery, Kumamoto University, School of Medicine, Honjo 1-1-1, Kumamoto City, Kumamoto 860, Japan

Received for publication Nov. 17, 1993. Accepted for publication July 12, 1994. Address for reprints: Toshitada Okuma, MD, Izumi City Hospital, 520 Myojin-cho, Izumi City, Kagoshima 899-01, Japan.

Abstract

To examine the role and significance of in vitro chemosensitivity testing on cells cultured from endoscopic biopsy specimens, we evaluated outcomes in 57 patients with squamous cell carcinoma of the thoracic esophagus. Over 31/2 years, 57 patients were treated with a single course of preoperative combination chemotherapy based on the results of chemosensitivity testing utilizing eight antineoplastic agents. A radiologically evident response (partial response) was seen in 23 patients (40.4%) and histologic effects on grade IIb tumors were seen in six patients (10.5%). The median survival time of all 57 patients was 16.3 months. The median survival time of nine patients who received palliative resection was 4.5 months. The median survival times after curative resection of the 19 patients with a partial response and 29 patients with no response were 27.7 months and 17.3 months, respectively (p < 0.009). The most frequent combination chemotherapy used was cis-dichlorodiammine platinum (II) vindesine/5-fluorouracil, and a high rate of response was noted after therapy with etoposide and 4'-D-tetrahydropyranyl-doxorubicin. Chemosensitivity testing appears to be useful in selecting preoperative chemotherapeutic agents for patients with esophageal cancer, decreasing tumor recurrence after surgery and resulting in more partial responses than conventional chemotherapy. (J THORACCARDIOVASCSURG1994;108:823-9)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1994 by The American Association for Thoracic Surgery.